New opportunities of drug therapy in patients with lung adenocarcinoma with ALK translocation

Nasretdinov A.F.; Sultanbaev A.V.; Menshikov K.V.; Musin Sh.I.; Sultanbaeva N.I.; Izmailov A.A.

doi:https://doi.org/10.17116/onkolog2020905148

Nasretdinov A.F.

Republican Clinical Oncology Dispensary

Sultanbaev A.V.

Republican Clinical Oncology Dispensary

Menshikov K.V.

Republican Clinical Oncology Dispensary;
Bashkir State Medical University

Musin Sh.I.

Republican Clinical Oncology Dispensary

Sultanbaeva N.I.

Republican Clinical Oncology Dispensary

Izmailov A.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

ORCID: 0000-0001-5836-0066

New opportunities of drug therapy in patients with lung adenocarcinoma with ALK translocation

Authors:

Nasretdinov A.F., Sultanbaev A.V., Menshikov K.V., Musin Sh.I., Sultanbaeva N.I., Izmailov A.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2020;9(5): 48‑52

DOI: 10.17116/onkolog2020905148

Read: 2139 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Nasretdinov AF, Sultanbaev AV, Menshikov KV, Musin ShI, Sultanbaeva NI, Izmailov AA. New opportunities of drug therapy in patients with lung adenocarcinoma with ALK translocation. P.A. Herzen Journal of Oncology. 2020;9(5):48‑52. (In Russ.)
https://doi.org/10.17116/onkolog2020905148

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Anatomic segmental lung resections for malignant neoplasms of the lung. P.A. Herzen Journal of Oncology. 2024;(5):69-75

Exosomal non-coding rnas as potential biomarkers in the diagnosis and prognosis of lung cancer. Review. Laboratory Service. 2024;(3):42-49

Cost of supportive cancer care in the Russian Federation. Part 2. Medical Technologies. Assessment and Choice. 2024;(4):63-73

The first thousand of VATS anatomical lung resections at the Herzen Moscow Oncology Research Institute. Pirogov Russian Journal of Surgery. 2025;(6):7-18

Prognostic model and calculator for assessing the risk of prolonged pleural effusion after lobectomy. Pirogov Russian Journal of Surgery. 2025;(6):26-34

Fibrosing interstitial lung disease as a risk factor for lung cancer: a review of the literature and clinical case report. Journal of Respiratory Medicine. 2025;(2):51-59

Survival of patients with malignant lung neoplasms in the Tomsk region (2013—2022). Russian Journal of Preventive Medicine. 2025;(7):43-49

Morphological examination of surgical material of primary lung cancer after neoadjuvant therapy: recommendations and literature review. Russian Journal of Archive of Pathology. 2025;(4):40-46

Abstract:

The paper deals with an analysis the efficacy and toxicity of alectinib, by using an example of treating clinical cases of anaplastic lymphoma kinase (ALK)-mutated non-small cell lung tumors. It describes two clinical cases of using alectinib in patients with lung adenocarcinoma with ALK translocation. The paper presents an individual approach to treating the patient and information on the side effects of different ALK inhibitors. The experience with alectinib demonstrates that the drug can be used long in the presence of its high efficiency and controlled safety profile.

Keywords:

lung cancer

ALK mutation

hepatotoxicity

tyrosine kinase inhibitors

alectinib

Authors:

Nasretdinov A.F.

Republican Clinical Oncology Dispensary

Sultanbaev A.V.

Republican Clinical Oncology Dispensary

Menshikov K.V.

Republican Clinical Oncology Dispensary;
Bashkir State Medical University

Musin Sh.I.

Republican Clinical Oncology Dispensary

Sultanbaeva N.I.

Republican Clinical Oncology Dispensary

Izmailov A.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

ORCID: 0000-0001-5836-0066

Received:

14.07.2020

Accepted:

30.07.2020

Close metadata

References:

Barlesi F, Mazieres J, Merlio JP. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415-1426. https://doi.org/10.1016/S0140-6736(16)00004
Demidova I, Grinevich V, Avdalian A, Imyanitov E, Gikalo M, Savelov N, Novikova I, Samuilenkova O, Tiurin V, Ulianova E, Tsimafeyeu I, Tjulandin S. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches. Lung Cancer. 2017;103:17-23. https://doi.org/1010.1016/j.lungcan.2016.11.001
Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36-54. https://doi.org/1010.3978/j.issn.2218-6751.2014.05.01
Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31(8):1105-1111. https://doi.org/1010.1200/JCO.2012.44.5353
Du X, Shao Y, Qin HF, Tai YH, Gao HJ. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer. 2018;9(4):423-430. https://doi.org/1010.1111/1759-7714.12613
Zhang I, Zaorsky NG, Palmer JD. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015;16:510-521.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-2177. https://doi.org/1010.1056/NEJMoa1408440
Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the Global Phase III ALEX Study. J Thorac Oncol. 2019;14(7):1233-1243. https://doi.org/10.1016/j.jtho.2019.03.007
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. Alectinib versus crizotinibin untreated ALK-positive non — small-cell lung cancer. N Engl J Med. 2017;377(9):829-838. https://doi.org/1010.1056/NEJMoa1704795
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288-2301. https://doi.org/1010.1056/NEJMoa1716948
Dumont D, Dô P, Lerouge D, Planchard G, Riffet M, Dubos-Arvis C, Danhier S, Gervais R. Off-label use of crizotinib as a neoadjuvant treatment for a young patient when conventional chemotherapy gave no benefits in stage IIIA non-small cell lung cancer. Am J Case Rep. 2017;18:890-893. https://doi.org/1010.12659/ajcr.903528
Sakanoue I, Hamakawa H, Kaji R, Imai Y, Katakami N, Takahashi Y. Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib. J Thorac Dis. 2018;10(3):170-174. https://doi.org/1010.21037/jtd.2018.02.03
Li J, Yuan Z, Wang Q, Fan W, Zhang G. Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer. Medicine (Baltimore). 2019;98(1):e13726. https://doi.org/1010.1097/MD.0000000000013726